

# Ventricular Tachycardia (Cardiovascular) - Drugs In Development, 2021

<https://marketpublishers.com/r/VFC68BF1F5C0EN.html>

Date: August 2021

Pages: 56

Price: US\$ 2,000.00 (Single User License)

ID: VFC68BF1F5C0EN

## Abstracts

Ventricular Tachycardia (Cardiovascular) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Drugs In Development, 2021, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape. Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness of breath. Causes include cardiomyopathy, ischemic heart disease and heart failure. Risk factors include age, family history and medical history. Treatment includes antiarrhythmic medication.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Ventricular Tachycardia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ventricular Tachycardia (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ventricular Tachycardia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ventricular Tachycardia (Cardiovascular)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Ventricular Tachycardia - Overview
- Ventricular Tachycardia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Ventricular Tachycardia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ventricular Tachycardia - Companies Involved in Therapeutics Development
- Academic Pharmaceuticals Inc
- Elex Biotech LLC
- GEXVal Inc
- HUYA Bioscience International LLC
- InCarda Therapeutics Inc
- Milestone Pharmaceuticals Inc
- Vivasc Therapeutics Inc
- Ventricular Tachycardia - Drug Profiles
- amiodarone - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- etripamil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- flecainide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- HBI-3000 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

Small Molecule for Cardiomyopathies and Catecholaminergic Polymorphic Ventricular Tachycardia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Ryanodine Receptor 2 for Catecholaminergic Polymorphic Ventricular Tachycardia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

soestelol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ventricular Tachycardia - Dormant Projects

Ventricular Tachycardia - Discontinued Products

Ventricular Tachycardia - Product Development Milestones

Featured News & Press Releases

May 17, 2021: Milestone Pharmaceuticals announces late-breaker oral presentation of NODE-301 data at ACC.21

Nov 18, 2020: Milestone Pharmaceuticals announces first patient enrolled in RAPID, a pivotal phase 3 study of etripamil in PSVT

Jul 23, 2020: Milestone Pharmaceuticals announces regulatory guidance and updated clinical development plan for Etripamil in PSVT

Mar 23, 2020: Milestone Pharmaceuticals announces topline results from first-of-its-kind phase 3 NODE-301 trial of etripamil for at-home acute PSVT treatment

Oct 03, 2019: Milestone Pharmaceuticals announces first patient enrolled in NODE-303 open-label safety study of Etripamil in PSVT

May 21, 2019: Milestone Pharmaceuticals presents studies on the economic impacts of PSVT at the ISPOR 2019 Annual Meeting

Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors

Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors

Aug 08, 2018: Milestone Pharmaceuticals announces first patient randomized in the

phase 3 NODE-301 clinical trial evaluating Etripamil for termination of paroxysmal supraventricular tachycardia (PSVT) episodes

May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions

Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer

Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias

Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name 'Etripamil' for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Ventricular Tachycardia, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Ventricular Tachycardia - Pipeline by Academic Pharmaceuticals Inc, 2021  
Ventricular Tachycardia - Pipeline by Elex Biotech LLC, 2021  
Ventricular Tachycardia - Pipeline by GEXVal Inc, 2021  
Ventricular Tachycardia - Pipeline by HUYA Bioscience International LLC, 2021  
Ventricular Tachycardia - Pipeline by InCarda Therapeutics Inc, 2021  
Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals Inc, 2021  
Ventricular Tachycardia - Pipeline by Vivasc Therapeutics Inc, 2021  
Ventricular Tachycardia - Dormant Projects, 2021  
Ventricular Tachycardia - Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Ventricular Tachycardia, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Stage and Molecule Types, 2021



## I would like to order

Product name: Ventricular Tachycardia (Cardiovascular) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/VFC68BF1F5C0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VFC68BF1F5C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970